文献速递类风湿关节炎脊柱关节炎其他结缔组织病

风湿病学中的生物类似药时代:重塑医疗环境

Era of biosimilars in rheumatology: reshaping the healthcare environment.
PubMed 文献 · RMD Open · 2019-05-21

本文综述了生物类似药(bsDMARDs)在风湿病领域的应用现状,指出其与原研生物药在理化特性、生物活性、疗效及安全性上高度相似,批准前需经严格研发流程验证。使用bsDMARDs或从原研药转换可显著节省成本,但转换可能引发反安慰剂效应,影响依从性,需通过充分沟通实现合理整合。

要点

  • 生物类似药与原研药疗效等效,安全性及免疫原性无临床显著差异。
  • 初治患者使用bsDMARDs或转换治疗可大幅节省成本。
  • 转换可能引发反安慰剂效应,需充分沟通以保障依从性。

核心结论

  • 生物类似药与原研生物药高度相似,疗效等效且安全性无临床显著差异。
  • 使用或转换至bsDMARDs可显著节省成本,但反安慰剂效应可能影响依从性。
  • 风湿科医生需向患者充分沟通bsDMARDs的节省成本效益与安全性以实现合理整合。

研究设计与样本

  • 本文为综述,未报告具体检索范围或样本量。

主要发现

  • 基于阿达木单抗、依那西普和英夫利西单抗的多种bsDMARDs已获批用于风湿病患者。
  • 生物类似药批准前需经严格研发流程验证与参照生物药的相似性。
  • 转换治疗可能出现主观疾病活动度增加和疼痛相关不良事件等反安慰剂反应。

关键数值与推荐

  • 生物类似药需与参照生物药具有高度相似的理化特性和生物活性。
  • 批准前需使用先进技术建立与参照产品的生物相似性。
  • 批准后需遵循生物药品良好药学规范。

临床怎么用

  • 生物类似药初治患者或转换治疗可节省成本。
  • 需向患者充分沟通bsDMARDs的节省成本效益与安全性以减少反安慰剂效应。
  • 关注转换后依从性,确保生物类似药在风湿病实践中的合理整合。

局限性

  • 本文为综述,未报告原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Compared with the original approved biological drug on which it is based, a biosimilar has highly similar physicochemical characteristics and biological activity, as well as equivalent efficacy and no clinically meaningful differences in safety and immunogenicity. Before they are approved, biosimilars must undergo a rigorous development process using state-of-the-art technologies to establish biosimilarity to the reference biological product. After approval, biosimilars must comply with good pharmacological practices for biological drugs. Several biosimilar disease-modifying antirheumatic drugs (bsDMARDs) based on the tumour necrosis factor inhibitors adalimumab, etanercept and infliximab have been approved for use in patients with rheumatic diseases. Substantial cost savings can be made if biological-naive patients begin treatment with bsDMARDs, and patients receiving original biological DMARDs (bDMARDs) are switched to bsDMARDs. Despite the consistently similar efficacy, safety and immunogenicity of bsDMARDs relative to their respective original bDMARDs, switching from a reference bDMARD to a bsDMARD can result in nocebo responses, such as subjective increase of disease activity and pain-related adverse events. This may have a negative impact on adherence to bsDMARDs in clinical trials and clinical practice. To ensure optimal and rational integration of bsDMARDs into rheumatology practice and realise the full cost-saving efficacy of these drugs, rheumatologists must be aware that careful communication of the cost-saving efficacy and safety of bsDMARDs to their patients is the key to a successful long-term switch to bsDMARD therapy.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019. PMID: 31245050. doi:10.1136/rmdopen-2019-000900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。